Robust induction of neutralizing antibodies against the SARS‐CoV‐2 Delta variant after homologous Spikevax or heterologous Vaxzevria‐Spikevax vaccination

Sera of vaccines were assessed by surrogate virus neutralization tests for their capacity to neutralize the SARS‐CoV‐2 Delta variant. Homologous prime‐boost immunization with Moderna's Spikevax as well as heterologous immunization with AstraZeneca's Vaxzevria followed by Moderna's Spi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hammerschmidt, Swantje I., Thurm, Christoph, Bošnjak, Berislav, Bernhardt, Günter, Reinhold, Annegret, Willenzon, Stefanie, Ritter, Christiane, Reinhold, Dirk, Schraven, Burkhart, Förster, Reinhold
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Notes and Insights
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015245/
https://www.ncbi.nlm.nih.gov/pubmed/34870322
http://dx.doi.org/10.1002/eji.202149645

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015245/
https://www.ncbi.nlm.nih.gov/pubmed/34870322
http://dx.doi.org/10.1002/eji.202149645

Ejemplares similares